0001178913-22-001022.txt : 20220309
0001178913-22-001022.hdr.sgml : 20220309
20220309160543
ACCESSION NUMBER: 0001178913-22-001022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220307
FILED AS OF DATE: 20220309
DATE AS OF CHANGE: 20220309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cohen Neil Harris
CENTRAL INDEX KEY: 0001840006
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 22725419
MAIL ADDRESS:
STREET 1: C/O ANCHIANO THERAPEUTICS LTD.
STREET 2: ONE KENDALL SQ., BLDG 1400E, STE 14-105
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
zk2227455.xml
X0306
4
2022-03-07
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001840006
Cohen Neil Harris
C/O CHEMOMAB THERAPEUTICS LTD.,
1 KENDALL SQ, BLDG 1400E, STE 14-105
CAMBRIDGE
MA
02139
1
0
0
0
American Depositary Shares
4409
D
Option to Purchase American Depositary Shares
3.53
2022-03-07
4
A
0
6820
0
A
2032-03-07
American Depositary Shares
6820
6820
D
Option to Purchase American Depositary Shares
27.26
2031-04-19
American Depositary Shares
11884
11884
D
Option to Purchase American Depositary Shares
13.17
2030-03-15
American Depositary Shares
688
688
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
These options vest and become exercisable in their entirety on March 16, 2023.
These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
These options vest and become exercisable as follows: 1/3 vest on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.
/s/ Neil Cohen
2022-03-09